4min chapter

Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Eyes of Pelobresso

The stock today is 27. At the current price, more than half of that value would be covered by the net cash at the end of this year. So you're paying for less than $13 per share net, you're getting Pelobresso which I think you guys think risk adjusted could be worth as much as $45 per share. We are active engagement in lifetimes. That's the exposure we give to our investors. And when we sat down with John Paul, who's the CEO here, we went through section A, section B, and we came to section C,. The reason why we thought they'd underperformed was obviously, we thought that Majouvi was potentially

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode